Bavarian Nordic

Dependence On Key Contracts Will Hamper Performance Yet Suggest Promise

AnalystLowTarget

Not Invested

Community Contributor

Published

18 Jul 25

Updated

16 Dec 25

Views

n/a

AnalystLowTarget's Fair Value

n/a

-1.9%

0.5%

-1.9%

0.5%

You can edit this narrative until Dec 17 7:05 PM. Then, changes will post as Updates.

Author's Valuation

DKK 25024.3% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 16 Dec 25

Fair value Increased 11%

BAVA: Mpox Preparedness Contracts Will Underpin Stronger Long Term Earnings Power

Analysts have raised their price target on Bavarian Nordic from approximately $225 to about $250. This reflects a higher justified valuation multiple despite expectations for softer revenue growth and margins.

AnalystLowTarget Fair Value

DKK 250

24.3% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

-0.21%

Biotech revenue growth rate

8.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.14%

Calculation

DKK 608.17m

Earnings '28

36.81x

PE Ratio '28

DKK 22.39b

Market Cap '28

DKK 22.39b

Market Cap '28

77.37m

No. shares '28

DKK 289.33

Share Price '28

DKK 289.33 Share Price '28

Discounted to 2025 @ 5.16% p.a.

DKK 248.79

Fair Value '25